Ginsenoside Rg1 abolish imiquimod‐induced psoriasis‐like dermatitis in BALB/c mice via downregulating NF‐κB signaling pathway
2019
Shi, Quan | He, Qi | Chen, Weiming | Long, Jianwen | Zhang, Bo
This animal experiment was framed to evaluate the beneficial effect of ginsenoside Rg1 (GRg1) against imiquimod (IMQ)‐induced psoriasis‐like dermatitis model to reveal the underpinning mechanism. Fifty healthy BALB/c mice were divided into five groups as control, GRg1, IMQ induced, oral treatment of GRg1 (50 mg/kg), or dexamethasone (DXM; 10 mg/kg) in IMQ‐induced mice. Treatment with GRg1 or DXM significantly mitigates (p < .01) psoriasis area severity index (PASI) score, skin thickness, lipid peroxidation, and inflammatory markers (IL‐23, 22, 17A, 1β, and TNF‐α). Moreover, administration of GRg1 or DXM considerably reversed the morphological changes induced by IMQ with improved (p < .01) antioxidant activity (SOD, CAT). In addition, a marked downregulation (p < .01) of protein expressions of pIκB and NF‐κB p65 (NF‐κB signaling pathway) were noted in GRg1 group. Collectively, GRg1 or DXM treatment significantly abolishes IMQ‐induced psoriasis‐like dermatitis by lowering PASI score, inflammation through downregulating NF‐κB signaling pathway. PRACTICAL APPLICATIONS: This is the very first study to explore the efficacy of ginsenoside Rg1 (GRg1) against IMQ‐induced psoriasis in the mice model to reveal the underpinning mechanism. The results clearly showed that GRg1 potent anti‐psoriasis activity by lowering PASI score, inflammation through downregulating NF‐κB signaling pathway. Hence, this study helps in the development of novel nutraceutical/functional food against psoriasis and thus could improve the quality of life in psoriasis patients. However, further clinical trials are needed to justify the above results before developing a commercial functional food using GRg1 against psoriasis.
显示更多 [+] 显示较少 [-]